Europe G-CSF PEG-G-CSF Market - Industry Trends and Forecast to 2030

Description

List of Tables

Europe G-CSF/ PEG-G-CSF market is projected to register a substantial CAGR of 5.1% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Europe G-CSF/PEG-G-CSF Market, By Indication (Neutropenia, Oncology, Chronic and Autoimmune Disease, Blood Disorders, Growth Harmony Deficiency and Others), Dosage (Mono and Combination), Route Of Administration (Intravenous, Subcutaneous), Packaging (Single Use Vials and Pre Filled Syringes), End User (Hospitals and Clinics, Research and Academic Institutes, Ambulatory Surgical Centers and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others), Country (Germany, U.K., France, Italy, Russia, Netherlands, Spain, Sweden, Poland, Belgium, Switzerland, Denmark, Norway, Finland, Turkey, Rest of Europe) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Europe G-CSF/PEG-G-CSF market are:

Growing incidences of blood cancers and cancer diseases

Increasing cases of febrile neutropenia

Market Players:

The key market players operating in the Europe G-CSF/PEG-G-CSF market are listed below:

Lupin

Intas Pharmaceuticals Ltd.

BIOSIDUS

STADA Arzneimittel AG

USV Private Limited

Viatris Inc.

Biocon

Fresenius Kabi AG

Amgen Inc.

Pfizer Inc.

Sandoz International GmbH

Cadila Pharmaceuticals

Dr. Reddy's Laboratories Ltd.

Amneal Pharmaceuticals LLC.

Accord Healthcare

Intas Pharmaceuticals Ltd.

Mundipharma International

Teva Pharmaceutical Industries Ltd.

Kyowa Kirin Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

1 INTRODUCTION 50

1.1 OBJECTIVES OF THE STUDY 50
1.2 MARKET DEFINITION 50
1.3 OVERVIEW OF EUROPE G-CSF / PEG-G-CSF MARKET 50
1.4 LIMITATIONS 52
1.5 MARKETS COVERED 52

2 MARKET SEGMENTATION 55

2.1 MARKETS COVERED 55
2.2 GEOGRAPHICAL SCOPE 56
2.3 YEARS CONSIDERED FOR THE STUDY 57
2.4 CURRENCY AND PRICING 57
2.5 DBMR TRIPOD DATA VALIDATION MODEL 58
2.6 MULTIVARIATE MODELLING 61
2.7 TYPE LIFELINE CURVE 61
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 62
2.9 DBMR MARKET POSITION GRID 63
2.10 MARKET END USER COVERAGE GRID 64
2.11 VENDOR SHARE ANALYSIS 65
2.12 SECONDARY SOURCES 66
2.13 ASSUMPTIONS 66

3 EXECUTIVE SUMMARY 67

4 PREMIUM INSIGHTS 70

4.1 PESTEL ANALYSIS 71
4.2 PORTER'S FIVE FORCES 72
4.3 EUROPE G-CSF/PEG-G-CSF MARKET: MERGERS AND ACQUISITION 73
4.4 EUROPE G-CSF / PEG-G-CSF MARKET 74
4.5 STRATEGIES TO THE ENTER THE MARKET 74
- 4.5.1 JOINT VENTURE (PARTNERSHIPS): 74
- 4.5.2 ACQUISITION: 74
- 4.5.3 LINE EXPANSION VIA COLLABORATION: 74
- 4.5.4 PRODUCT APPROVAL: 75
- 4.5.5 PRODUCT LAUNCH: 75
- 4.5.6 GEOGRAPHIC EXPANSION: 75
- 4.5.7 COST LEADERSHIP: 76
- 4.5.8 PRODUCT DEVELOPMENT: 76
4.6 EUROPE G-CSF / PEG-G-CSF MARKET, INDUSTRY INSIGHTS 77
- 4.6.1 PATENT ANALYSIS 77
- 4.6.2 DRUG TREATMENT RATE BY MATURED MARKETS 78
- 4.6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 78
- 4.6.4 THERAPEUTIC ASSESSMENT 78
- 4.6.5 KEY PRICING STRATEGIES 79
- 4.6.6 KEY PATIENT ENROLLMENT STRATEGIES 79
- 4.6.7 CONCLUSION 79
4.7 PIPELINE ANALYSIS FOR EUROPE G-CSF / PEG-G-CSF MARKET 80

5 EPIDEMIOLOGY 81

6 EUROPE G-CSF / PEG-G-CSF MARKET: REGULATIONS 84

7 MARKET OVERVIEW 87

7.1 DRIVERS 89
- 7.1.1 GROWING INCIDENCES OF BLOOD CANCERS AND CANCER DISEASES 89
- 7.1.2 RISING INCIDENCES OF AUTOIMMUNE DISORDERS 90
- 7.1.3 INCREASING CASES OF FEBRILE NEUTROPENIA 91
- 7.1.4 INCREASING AWARENESS ABOUT FILGRASTIM AND PEGFILGRASTIM 92
7.2 RESTRAIN 93
- 7.2.1 STRINGENT GOVERNMENTAL REGULATIONS 93
- 7.2.2 AVAILABILITY OF ALTERNATIVES FOR THE CHEMOTHERAPY 94
7.3 OPPORTUNITIES 95
- 7.3.1 THE USE OF BIOSIMILARS HELPS REDUCE HEALTHCARE COSTS FOR PATIENTS 95
- 7.3.2 COST-EFFECTIVENESS AND PATENT EXPIRY OF BIOLOGICAL PRODUCTS 95
7.4 CHALLENGES 96
- 7.4.1 THE HIGH COST ASSOCIATED WITH BRANDED BIOLOGICS AND IMPROVED CHEMOTHERAPY 96
- 7.4.2 THE MULTIPLE SIDE EFFECTS OF G-CSF 96

8 EUROPE G-CSF/ PEG-G-CSF MARKET, BY INDICATION 97

8.1 OVERVIEW 98
8.2 NEUTROPENIA 102
- 8.2.1 CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT) 103
- 8.2.2 SEVERE CHRONIC NEUTROPENIA 103
- 8.2.3 RADIOTHERAPY INDUCED NEUTROPENIA 103
- 8.2.4 NEUTROPENIA IN HIV PATIENTS 103
- 8.2.5 CLOZAPINE INDUCED NEUTROPENIA 103
- 8.2.6 NEUTROPENIA IN HEPATITIS C PATIENTS 103
- 8.2.7 CONGENITAL NEUTROPENIA 103
8.3 ONCOLOGY 104
- 8.3.1 ACUTE MYELOID LEUKEMIA RECEIVING CONSOLIDATION CHEMOTHERAPY 104
- 8.3.2 OTHERS 105
8.4 CHRONIC AND AUTO IMMUNE DISEASES 105
8.5 BLOOD DISORDERS 105
8.6 GROWTH HORMONE DEFICIENCY 106
8.7 OTHERS 107

9 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DOSAGE 108

9.1 OVERVIEW 109
9.2 MONO 112
9.3 COMBINATION 113

10 EUROPE G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION 114

10.1 OVERVIEW 115
10.2 SUBCUTANEOUS 118
10.3 INTRAVENOUS 119

11 EUROPE G-CSF/ PEG-G-CSF MARKET, BY PACKAGING 120

11.1 OVERVIEW 121
11.2 PRE FILLED SYRINGES 124
11.3 SINGLE USE VIALS 125

12 EUROPE G-CSF/ PEG-G-CSF MARKET, BY END USER 126

12.1 OVERVIEW 127
12.2 HOSPITALS AND CLINICS 130
12.3 RESEARCH & ACADEMIC INSTITUTES 130
12.4 AMBULATORY SURGICAL CENTERS 131
12.5 OTHERS 132

13 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL 133

13.1 OVERVIEW 134
13.2 HOSPITALS PHARMACY 137
13.3 RETAIL PHARMACY 137
13.4 ONLINE PHARMACY 138
13.5 OTHERS 139

14 EUROPE G-CSF/PEG-G-CSF MARKET, BY REGION 140

14.1 EUROPE 141
- 14.1.1 RUSSIA 148
- 14.1.2 TURKEY 156

15 EUROPE G-CSF / PEG-G-CSF MARKET, COMPANY LANDSCAPE 167

15.1 COMPANY SHARE ANALYSIS: EUROPE 167

16 SWOT ANALYSIS 168

17 COMPANY PROFILE 169

17.1 PFIZER INC. 169
- 17.1.1 COMPANY SNAPSHOT 169
- 17.1.2 REVENUE ANALYSIS 170
- 17.1.3 COMPANY SHARE ANALYSIS 170
- 17.1.4 PRODUCT PORTFOLIO 171
- 17.1.5 RECENT DEVELOPMENTS 171
17.2 VIATRIS INC. 172
- 17.2.1 COMPANY SNAPSHOT 172
- 17.2.2 REVENUE ANALYSIS 172
- 17.2.3 COMPANY SHARE ANALYSIS 173
- 17.2.4 PRODUCT PORTFOLIO 173
- 17.2.5 RECENT DEVELOPMENT 173
17.3 AMGEN INC. 174
- 17.3.1 COMPANY SNAPSHOT 174
- 17.3.2 REVENUE ANALYSIS 174
- 17.3.3 COMPANY SHARE ANALYSIS 175
- 17.3.4 PRODUCT PORTFOLIO 175
- 17.3.5 RECENT DEVELOPMENTS 175
17.4 STADA ARZENEIMITTEL AG 177
- 17.4.1 COMPANY SNAPSHOT 177
- 17.4.2 COMPANY SHARE ANALYSIS 177
- 17.4.3 PRODUCT PORTFOLIO 178
- 17.4.4 RECENT DEVELOPMENT 178
17.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 179
- 17.5.1 COMPANY SNAPSHOT 179
- 17.5.2 REVENUE ANALYSIS 179
- 17.5.3 COMPANY SHARE ANALYSIS 180
- 17.5.4 PRODUCT PORTFOLIO 180
- 17.5.5 RECENT DEVELOPMENTS 180
17.6 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 181
- 17.6.1 COMPANY SNAPSHOT 181
- 17.6.2 PRODUCT PORTFOLIO 181
- 17.6.3 RECENT DEVELOPMENTS 181
17.7 ACCORD HEALTHCARE 182
- 17.7.1 COMPANY SNAPSHOT 182
- 17.7.2 PRODUCT PORTFOLIO 182
- 17.7.3 RECENT DEVELOPMENTS 182
17.8 AMNEAL PHARMACEUTICALS LLC. 183
- 17.8.1 COMPANY SNAPSHOT 183
- 17.8.2 REVENUE ANALYSIS 183
- 17.8.3 PRODUCT PORTFOLIO 184
- 17.8.4 RECENT DEVELOPMENTS 184
17.9 APOTEX INC. 185
- 17.9.1 COMPANY SNAPSHOT 185
- 17.9.2 PRODUCT PORTFOLIO 185
- 17.9.3 RECENT DEVELOPMENT 185
17.10 BIOCON 186
- 17.10.1 COMPANY SNAPSHOT 186
- 17.10.2 REVENUE ANALYSIS 186
- 17.10.3 PRODUCT PORTFOLIO 187
- 17.10.4 RECENT DEVELOPMENT 187
17.11 BIO SIDUS 188
- 17.11.1 COMPANY SNAPSHOT 188
- 17.11.2 PRODUCT PORTFOLIO 188
- 17.11.3 RECENT DEVELOPMENTS 188
17.12 CADILA PHARMACEUTICALS 189
- 17.12.1 COMPANY SNAPSHOT 189
- 17.12.2 PRODUCT PORTFOLIO 189
- 17.12.3 RECENT DEVELOPMENTS 189
17.13 COHERUS BIOSCIENCES 190
- 17.13.1 COMPANY SNAPSHOT 190
- 17.13.2 REVENUE ANALYSIS 190
- 17.13.3 PRODUCT PORTFOLIO 191
- 17.13.4 RECENT DEVELOPMENT 191
17.14 DR. REDDY'S LABORATORIES LTD 192
- 17.14.1 COMPANY SNAPSHOT 192
- 17.14.2 REVENUE ANALYSIS 192
- 17.14.3 PRODUCT PORTFOLIO 193
- 17.14.4 RECENT DEVELOPMENTS 193
17.15 FRESENIUS KABI AG 194
- 17.15.1 COMPANY SNAPSHOT 194
- 17.15.2 PRODUCT PORTFOLIO 194
- 17.15.3 RECENT DEVELOPMENT 194
17.16 GENNOVA BIOPHARMACEUTICALS LIMITED 195
- 17.16.1 COMPANY SNAPSHOT 195
- 17.16.2 PRODUCT PORTFOLIO 195
- 17.16.3 RECENT DEVELOPMENTS 195
17.17 HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD. 196
- 17.17.1 COMPANY SNAPSHOT 196
- 17.17.2 PRODUCT PORTFOLIO 196
- 17.17.3 RECENT DEVELOPMENTS 196
17.18 INTAS PHARMACEUTICALS LTD. 197
- 17.18.1 COMPANY SNAPSHOT 197
- 17.18.2 PRODUCT PORTFOLIO 197
- 17.18.3 RECENT DEVELOPMENT 197
17.19 KASHIV BIOSCIENCES, LLC. 198
- 17.19.1 COMPANY SNAPSHOT 198
- 17.19.2 PRODUCT PORTFOLIO 198
- 17.19.3 RECENT DEVELOPMENT 198
17.20 KYOWA KIRIN CO., LTD. 199
- 17.20.1 COMPANY SNAPSHOT 199
- 17.20.2 REVENUE ANALYSIS 199
- 17.20.3 PRODUCT PORTFOLIO 200
- 17.20.4 RECENT DEVELOPMENT 200
17.21 LUPIN 201
- 17.21.1 COMPANY SNAPSHOT 201
- 17.21.2 REVENUE ANALYSIS 201
- 17.21.3 PRODUCT PORTFOLIO 202
- 17.21.4 RECENT DEVELOPMENT 202
17.22 MUNDIPHARMA INTERNATIONAL. 203
- 17.22.1 COMPANY SNAPSHOT 203
- 17.22.2 PRODUCT PORTFOLIO 203
- 17.22.3 RECENT DEVELOPMENT 203
17.23 NAPP PHARMACEUTICALS LIMITED 204
- 17.23.1 COMPANY SNAPSHOT 204
- 17.23.2 PRODUCT PORTFOLIO 204
- 17.23.3 RECENT DEVELOPMENT 204
17.24 RELIANCE LIFE SCIENCES 205
- 17.24.1 COMPANY SNAPSHOT 205
- 17.24.2 PRODUCT PORTFOLIO 205
- 17.24.3 RECENT DEVELOPMENTS 205
17.25 SANDOZ INTERNATIONAL GMBH 206
- 17.25.1 COMPANY SNAPSHOT 206
- 17.25.2 REVENUE ANALYSIS 206
- 17.25.3 PRODUCT PORTFOLIO 207
- 17.25.4 RECENT DEVELOPMENTS 207
17.26 SPECTRUM PHARMACEUTICALS, INC. 208
- 17.26.1 COMPANY SNAPSHOT 208
- 17.26.2 PRODUCT PORTFOLIO 208
- 17.26.3 RECENT DEVELOPMENT 208
17.27 USV PRIVATE LIMITED 209
- 17.27.1 COMPANY SNAPSHOT 209
- 17.27.2 PRODUCT PORTFOLIO 209
- 17.27.3 RECENT DEVELOPMENTS 209

18 QUESTIONNAIRE 210

19 RELATED REPORTS 213

LIST OF FIGURES

FIGURE 1 EUROPE G-CSF / PEG-G-CSF MARKET: SEGMENTATION 22
FIGURE 2 EUROPE G-CSF / PEG-G-CSF MARKET: DATA TRIANGULATION 25
FIGURE 3 EUROPE G-CSF / PEG-G-CSF MARKET: DROC ANALYSIS 26
FIGURE 4 EUROPE G-CSF / PEG-G-CSF MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 27
FIGURE 5 EUROPE G-CSF / PEG-G-CSF MARKET: COMPANY RESEARCH ANALYSIS 27
FIGURE 6 EUROPE G-CSF / PEG-G-CSF MARKET: INTERVIEW DEMOGRAPHICS 29
FIGURE 7 EUROPE G-CSF / PEG-G-CSF MARKET: DBMR MARKET POSITION GRID 30
FIGURE 8 EUROPE G-CSF / PEG-G-CSF MARKET: MARKET END USER COVERAGE GRID 31
FIGURE 9 EUROPE G-CSF / PEG-G-CSF MARKET: VENDOR SHARE ANALYSIS 32
FIGURE 10 EUROPE G-CSF / PEG-G-CSF MARKET: SEGMENTATION 36
FIGURE 11 THE INCREASE IN CANCER PROPHYLAXIS IN DEVELOPED COUNTRIES AND INITIATIVES TAKEN BY GOVERNMENTS ARE TO DRIVE THE EUROPE G-CSF / PEG-G-CSF MARKET FROM 2023 TO 2030 37
FIGURE 12 NEUTROPENIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE G-CSF / PEG-G-CSF MARKET IN 2023 & 2030 37
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE G-CSF / PEG-G-CSF MARKET 55
FIGURE 14 EUROPE G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2022 66
FIGURE 15 EUROPE G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2021-2030 (USD MILLION) 67
FIGURE 16 EUROPE G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, CAGR (2022-2029) 67
FIGURE 17 EUROPE G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, LIFELINE CURVE 68
FIGURE 18 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2022 76
FIGURE 19 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2021-2030 (USD MILLION) 77
FIGURE 20 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, CAGR (2023-2030) 77
FIGURE 21 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, LIFELINE CURVE 78
FIGURE 22 EUROPE G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2022 82
FIGURE 23 EUROPE G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 83
FIGURE 24 EUROPE G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 83
FIGURE 25 EUROPE G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 84
FIGURE 26 EUROPE G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2022 88
FIGURE 27 EUROPE G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2021-2030 (USD MILLION) 89
FIGURE 28 EUROPE G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, CAGR (2023-2030) 89
FIGURE 29 EUROPE G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, LIFELINE CURVE 90
FIGURE 30 EUROPE G-CSF/ PEG-G-CSF MARKET: BY END USER, 2022 94
FIGURE 31 EUROPE G-CSF/ PEG-G-CSF MARKET: BY END USER, 2021-2030 (USD MILLION) 95
FIGURE 32 EUROPE G-CSF/ PEG-G-CSF MARKET: BY END USER, CAGR (2023-2030) 95
FIGURE 33 EUROPE G-CSF/ PEG-G-CSF MARKET: BY END USER, LIFELINE CURVE 96
FIGURE 34 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2022 101
FIGURE 35 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 102
FIGURE 36 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 102
FIGURE 37 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 103
FIGURE 38 EUROPE G-CSF/PEG-G-CSF MARKET: SNAPSHOT (2022) 108
FIGURE 39 EUROPE G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022) 109
FIGURE 40 EUROPE G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030) 109
FIGURE 41 EUROPE G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030) 110
FIGURE 42 EUROPE G-CSF/PEG-G-CSF MARKET: BY INDICATION (2023-2030) 110
FIGURE 43 EUROPE G-CSF / PEG-G-CSF MARKET: COMPANY SHARE 2022 (%) 134